The Technical Analyst
Select Language :
Immuron Limited [IMRN]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Immuron Limited Price, Forecast, Insider, Ratings, Fundamentals & Signals

Immuron Limited is listed at the  Exchange

-5.05% $2.63

America/New_York / 28 mar 2024 @ 16:00


Immuron Limited: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 14.99 mill
EPS: -0.440
P/E: -5.98
Earnings Date: Aug 30, 2024
SharesOutstanding: 5.70 mill
Avg Daily Volume: 0.928 mill
RATING 2024-03-28
B
Neutral
RATINGS
Rating CashFlow: Buy
Return On Equity: Sell
Return On Asset: Sell
DE: Sell
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
2/223/224/221/232/234/23
Revenuen/an/an/a
Gr.Profitn/an/an/a
Ebitn/an/an/a
Asset n/an/an/an/a
Debtn/an/an/an/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -5.98 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-1.02x
Company: PE -5.98 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 2.20 - 3.06

( +/- 16.39%)
ATR Model: 14 days

Forecast: 16:00 - $2.63

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $2.63
Forecast 2: 16:00 - $2.63
Forecast 3: 16:00 - $2.63
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $2.63 (-5.05% )
Volume 0.0281 mill
Avg. Vol. 0.928 mill
% of Avg. Vol 3.03 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Immuron Limited

Last 12 Months

Last 12 months chart data with high, low, open and close for Immuron Limited

RSI

Last 10 Buy & Sell Signals For IMRN

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Immuron Limited

IMRN

Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.

Last 10 Buy Signals

Date Signal @
FTNUSDMar 29 - 04:141.819
ORAIUSDMar 29 - 04:0814.59
IONUSDMar 29 - 04:08452.00
MXUSDMar 29 - 04:07$4.21
RETHUSDMar 29 - 04:043 905.62
ABTUSDMar 29 - 04:041.978
XU100.ISMar 29 - 04:03PTS9 101.28
DYDXUSDMar 29 - 04:003.39
^KLSEMar 29 - 03:46PTS1 536.68
WSTETHUSDMar 29 - 03:594 101.01

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.